Phase 2 Ovarian Clinical Trials
183 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 183 trials
Recruiting
Phase 2
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
Recurrent Ovarian CarcinomaRecurrent Endometrial CarcinomaRecurrent Fallopian Tube Carcinoma+1 more
National Cancer Institute (NCI)165 enrolled296 locationsNCT05554328
Recruiting
Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Metastatic Breast CarcinomaMetastatic Ovarian CancerMetastatic Pancreatic Cancer+2 more
National Cancer Institute (NCI)332 enrolled1 locationNCT01174121
Recruiting
Phase 2
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc310 enrolled91 locationsNCT05128825
Recruiting
Phase 2
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Gastric CancerOvarian CancerCholangiocarcinoma+7 more
National Cancer Institute (NCI)320 enrolled1 locationNCT06503146
Recruiting
Phase 1Phase 2
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Pancreatic Adenocarcinoma+2 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.230 enrolled13 locationsNCT05985655
Recruiting
Phase 2
Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression
Ovarian CancerOligometastatic DiseaseSerous Ovarian Tumor
MedSIR30 enrolled14 locationsNCT06180356
Recruiting
Phase 2
Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy
Ovarian CancerOvarian Cancer Metastatic RecurrentOvarian Cancer (OvCa)+1 more
Yonsei University116 enrolled1 locationNCT07340164
Recruiting
Phase 2
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors
Ovarian CancerCervical Cancer
Shanghai Henlius Biotech190 enrolled1 locationNCT06769152
Recruiting
Phase 2
Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.
Ovarian CancerSolid Tumor MalignanciesClear Cell Endometrial Carcinoma
Gustave Roussy, Cancer Campus, Grand Paris900 enrolled4 locationsNCT07303387
Recruiting
Phase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Colorectal CarcinomaAdvanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+41 more
Mayo Clinic220 enrolled2 locationsNCT05969860
Recruiting
Phase 2
A Study of Isoquercetin in People With Ovarian Cancer
Ovarian CancerEpithelial Ovarian CancerSerous Ovarian Tumor
Memorial Sloan Kettering Cancer Center90 enrolled8 locationsNCT07303894
Recruiting
Phase 1Phase 2
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
Ovarian CancerPancreatic CarcinomaAdvanced Solid Tumors+1 more
Evopoint Biosciences Inc.350 enrolled24 locationsNCT06799637
Recruiting
Phase 2
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
Ovarian Cancer
M.D. Anderson Cancer Center30 enrolled1 locationNCT05123807
Recruiting
Phase 2
Agnostic Therapy in Rare Solid Tumors
Cancer of Unknown PrimarySoft Tissue SarcomaCholangiocarcinoma+38 more
Instituto do Cancer do Estado de São Paulo28 enrolled8 locationsNCT06638931
Recruiting
Phase 1Phase 2
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Imunon30 enrolled4 locationsNCT05739981
Recruiting
Phase 2
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Ovarian Cancer
Incyte Corporation160 enrolled81 locationsNCT07023627
Recruiting
Phase 2
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Ovarian CancerEndometrial CancerFallopian Tube Cancer+1 more
Corcept Therapeutics270 enrolled49 locationsNCT06906341
Recruiting
Phase 2
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Primary Peritoneal CancerFallopian Tube CancerNeoadjuvant+1 more
AbbVie140 enrolled57 locationsNCT06890338
Recruiting
Phase 2
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+28 more
National Cancer Institute (NCI)36 enrolled4 locationsNCT04550494